BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
July 18 2024 - 5:30AM
Business Wire
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
oncology company, today announced the appointment of Aaron
Rosenberg as Chief Financial Officer, effective July 22. Mr.
Rosenberg will succeed Julia Wang, who is departing to pursue
external opportunities and will stay with the Company through
August to support the transition.
“We are thrilled to welcome Aaron amid a transformational year
for BeiGene as we became a top 15 global oncology innovator by
revenue with sustained progress to profitability and one of the
most prolific and innovative pipelines in our industry including a
plan to have at least 10 new molecular entities this year. Aaron’s
financial leadership and impressive track record at Merck & Co.
will be invaluable as we continue to responsibly scale our business
and look to reinforce our global leadership in hematology as well
as build future franchises in other highly prevalent cancers,
including lung, breast and gastrointestinal,” said John V. Oyler,
Co-Founder, Chairman and CEO of BeiGene. “We extend our deep
gratitude to Julia for her many significant contributions including
scaling our financial capabilities to support our growth from 4,000
to over 10,000 employees across five continents, contributing to
the launch of BRUKINSA®, which is one of the most successful global
drug launches in oncology, raising billions of dollars in capital
from the global equity markets and helping drive financial
excellence to improve operational efficiency. We wish Julia well in
her future endeavors.”
Mr. Rosenberg is a global finance executive with more than 20
years of experience at Merck & Co., Inc, known as Merck Sharp
& Dohme outside of the United States and Canada. He was most
recently Senior Vice President and Corporate Treasurer of Merck
from 2021.
“I’m honored to join BeiGene at an inflection point in the
Company’s growth with the opportunity to further strengthen this
resilient global financial organization,” said Mr. Rosenberg. “I
deeply believe in BeiGene’s mission to develop and deliver
innovative cancer medicines to more patients around the world, and
I’m excited to be a part of this growing company and its
experienced leadership team.”
Prior to his role as Corporate Treasurer, Mr. Rosenberg served
as Senior Vice President of Corporate Strategy and Planning at
Merck from 2018 to 2021 with responsibilities including leading the
enterprise-wide business transformation team and acting as Head of
Financial Planning & Analysis. Mr. Rosenberg was Vice President
and Finance Lead of Merck Animal Health from 2015 to 2018, leading
a global team of 120 colleagues. He joined Merck in 2003 in
ascending leadership roles in the global finance organization.
Mr. Rosenberg received a Bachelor of Science in Finance from the
Warrington College of Business at the University of Florida and a
Master of Business Administration from the Leonard N. Stern School
of Business at New York University.
About BeiGene
BeiGene is a global oncology company that is discovering and
developing innovative treatments that are more affordable and
accessible to cancer patients worldwide. With a broad portfolio, we
are expediting development of our diverse pipeline of novel
therapeutics through our internal capabilities and collaborations.
We are committed to radically improving access to medicines for far
more patients who need them. Our growing global team of more than
10,000 colleagues spans five continents. To learn more about
BeiGene, please visit www.beigene.com and follow us on LinkedIn, X
(formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
BeiGene’s planned number of new molecular entities this year;
BeiGene’s sustained progress towards profitability; BeiGene’s
ability to responsibly scale business and build future franchises
in other highly prevalent cancers; and BeiGene’s plans,
commitments, aspirations and goals under the caption “About
BeiGene”. Actual results may differ materially from those indicated
in the forward-looking statements as a result of various important
factors, including BeiGene’s ability to demonstrate the efficacy
and safety of its drug candidates; the clinical results for its
drug candidates, which may not support further development or
marketing approval; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials and
marketing approval; BeiGene’s ability to achieve commercial success
for its marketed medicines and drug candidates, if approved;
BeiGene's ability to obtain and maintain protection of intellectual
property for its medicines and technology; BeiGene’s reliance on
third parties to conduct drug development, manufacturing,
commercialization, and other services; BeiGene’s limited experience
in obtaining regulatory approvals and commercializing
pharmaceutical products; BeiGene’s ability to obtain additional
funding for operations and to complete the development of its drug
candidates and achieve and maintain profitability; and those risks
more fully discussed in the section entitled “Risk Factors” in
BeiGene’s most recent quarterly report on Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in BeiGene’s subsequent filings with the U.S. Securities
and Exchange Commission. All information in this press release is
as of the date of this press release, and BeiGene undertakes no
duty to update such information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240718157915/en/
Investors Liza Heapes +1 857-302-5663 ir@beigene.com
Media Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jul 2023 to Jul 2024